Puberty blockers trial paused over concerns from medicines watchdog
#Puberty blockers#MHRA#King's College London#Gender identity#Clinical trial#Transgender youth#Medical ethics#Informed consent
📌 Key Takeaways
MHRA has paused a puberty blockers clinical trial due to safety concerns
The trial was set to involve over 220 children aged 11-15
Regulatory agency wants minimum age raised to 14 with enhanced monitoring
The trial faces legal challenges and medical skepticism
📖 Full Retelling
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has paused a clinical trial assessing puberty-blocking drugs for children questioning their gender, citing safety concerns, with King's College London researchers leading the study that was set to involve over 220 participants aged 11-15. The trial, named Pathways, was approved last November by both the MHRA and Health Research Authority but has now been put on hold as the regulatory agency requests more stringent safety measures, including raising the minimum participant age to 14 and implementing enhanced monitoring of bone density. In a letter published on the government website, the MHRA expressed concerns about 'potentially significant and, as yet, unquantified risk of long-term biological harms' to younger participants, though they emphasized that safety discussions are part of the normal clinical trial process. The Department of Health & Social Care confirmed that participant recruitment will not resume until the concerns are resolved, maintaining that the trial will only proceed if expert scientific evidence concludes it is both safe and necessary. Meanwhile, the trial has faced opposition from some medical professionals who question its necessity and from campaigners pursuing legal action, claiming it is unethical for children to consent to treatments that might affect their future fertility, while Dr. Hilary Cass, whose 2024 review led to the ban on puberty blockers for under-18s, has argued that such trials are vital to prevent inappropriate drug distribution.
🏷️ Themes
Medical Regulation, Gender Treatment, Clinical Trials, Child Safety
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and ...
Transgender youth are children or adolescents who do not identify with the gender associated with the sex they were assigned at birth. Because transgender youth usually depend on their parents for care, shelter, financial support, and other needs, they face different challenges than transgender adul...
Gender identity is the personal sense of one's own gender. Gender identity can correspond to a person's assigned sex or can differ from it. In most individuals, the various biological determinants of sex are congruent and consistent with the individual's gender identity.
Puberty blockers (also called puberty inhibitors or hormone blockers) are medicines used to postpone puberty in children. The most commonly used puberty blockers are gonadotropin-releasing hormone (GnRH) agonists, which suppress the natural production of sex hormones, such as androgens (e.g. testost...
The pause highlights safety concerns about puberty blockers for minors and the regulatory oversight required for trials involving vulnerable children. It underscores the need for rigorous evidence before expanding treatment options for gender‑diverse youth.
Context & Background
UK Medicines and Healthcare Products Regulatory Agency (MHRA) paused a trial of puberty blockers for children aged 11‑15
The trial, called Pathways, was led by King's College London and aimed to assess physical and emotional impacts
The MHRA suggested raising the minimum age to 14 and adding stricter monitoring and consent procedures
What Happens Next
The MHRA will meet with the trial team next week to discuss the concerns and potential adjustments. If the issues are resolved, recruitment may resume; otherwise the trial could be cancelled or further delayed.
Frequently Asked Questions
Why was the trial paused?
The MHRA raised safety concerns about the age limit and monitoring of bone density, and requested a more rigorous consent process.
What is the current status of puberty blockers for under‑18s?
They were banned in 2024, but the trial seeks to gather evidence to potentially allow use for those 16 and older.
Will the trial be cancelled?
Not yet; the government said it will only proceed if scientific evidence confirms safety and necessity, and talks are ongoing.
Original Source
Puberty blockers trial paused over concerns from medicines watchdog 4 hours ago Share Save Amy Walker and Alison Holt , Social affairs editor Share Save A clinical trial assessing the risks and benefits of puberty-blocking drugs in children who question their gender has been paused after safety concerns were raised by the UK medicines watchdog. The Medicines and Healthcare Products Regulatory Agency is set to hold talks with King's College London, whose researchers are leading the trial, next week to address concerns, the government said. Details of the trial, which would involve more than 220 children aged between about 11 and 15, were announced in November after getting approval from the MHRA and Health Research Authority. An MHRA spokesperson said the "safety and wellbeing" of participants - yet to be recruited - was "paramount". Puberty blockers for people under-18 questioning their gender identity were banned in 2024 . The drugs, also known as puberty suppressing hormones , are used to delay or prevent puberty happening. The clinical trial, called Pathways, was set to involve children who are distressed about their gender and currently accessing gender services. It would examine the impact of the drugs on their physical, social and emotional wellbeing. But the MHRA has suggested the minimum age limit of those taking part should be increased to 14, and that there should be more detailed monitoring of bone density and a more rigorous consent process for participants. In a letter published on the government website on Friday, the MHRA expressed concern over the current age limit for participants in the trial. "Since potentially significant and, as yet, unquantified risk of long-term biological harms is present to participants and biological safety has not been definitively demonstrated in this proposed cohort, at the very least, there should be a graded/stepwise approach starting with those aged 14 as the lower limit of eligibility," it reads. In a separate statem...
